XML 40 R19.htm IDEA: XBRL DOCUMENT v3.25.4
FINANCIAL INSTRUMENTS
 12 Months Ended
Dec. 31, 2025
Investments, All Other Investments [Abstract]  
FINANCIAL INSTRUMENTS FINANCIAL INSTRUMENTS
The following table presents our financial instruments:
December 31, 2025December 31, 2024
Cash and cash equivalents$1,015,400 $744,721 
Available-for-sale investments142,498 34,015 
Equity investment10,000 10,000 
Total$1,167,898 $788,736 
Cash and cash equivalents consist primarily of money market funds with original maturity dates of three months or less, for which we determine fair value through quoted market prices.
Our investment portfolio is classified as available-for-sale in order to have the flexibility to buy and sell investments and maximize cash liquidity. Our available-for-sale investments primarily consist of investment grade corporate bonds, U.S. Treasuries, and asset-backed securities with maturity dates through 2027. These investments are presented at fair value and are included in short-term investments and non-current investments in the accompanying consolidated balance sheets. Unrealized gains or losses associated with the investments are included in accumulated other comprehensive income (loss), net of tax in the accompanying consolidated balance sheets and other comprehensive income (loss), net of tax in the statements of comprehensive income. For our available-for-sale investments, we do not have the intent to sell, nor is it more likely than not that we would be required to sell before recovery of their cost basis.
As of December 31, 2025 and 2024, we have an accrued interest receivable balance of approximately $1.3 million and $227,000, respectively, which is included in accounts receivable, net. We do not measure an allowance for credit losses for accrued interest receivables. We record any losses within the maturity period or at the time of sale of the investment and any write-offs to accrued interest receivables are recorded as reductions to interest income in the period of the loss. During the twelve months ended December 31, 2025, we have recorded no losses for accrued interest receivables. Interest income and amortization of discounts and premiums are included in other income, net in the accompanying consolidated statements of income.
The following table presents the components of our available-for-sale investments:
December 31, 2025December 31, 2024
Amortized cost$142,515 $34,225 
Unrealized gains127 3 
Unrealized losses(144)(213)
Estimated fair value$142,498 $34,015 
As of December 31, 2025, we have $81.8 million of available-for-sale debt securities with contractual maturities of one year or less and $60.7 million with contractual maturities greater than one year. As of December 31, 2025, 11 available-for-sale securities with a fair value of $8.9 million have been in a loss position for one year or less and four securities with a fair value of $6.1 million have been in a loss position for greater than one year.
The following table presents the activity on our available-for-sale investments:
Years Ended December 31,
202520242023
Proceeds from sales and maturities$121,890 $15,994 $49,412 
Realized gains (losses) on sales, net of tax6 (18)— 
Our equity investment consists of a minority interest in the common stock of a privately held company that is carried at cost less any impairment write-downs because we do not have the ability to exercise significant influence over the investee and the securities do not have readily determinable fair values. On February 2, 2026, we signed a definitive agreement to acquire the remaining equity interest of this investment. See Note 20 “Subsequent Events” for more information.